Terns Pharmaceuticals (NASDAQ:TERN) Earns “Equal Weight” Rating from Barclays

Terns Pharmaceuticals (NASDAQ:TERN)‘s stock had its “equal weight” rating reissued by investment analysts at Barclays in a report released on Monday,Benzinga reports. They currently have a $53.00 price target on the stock, down from their previous price target of $56.00. Barclays‘s target price would suggest a potential upside of 0.24% from the stock’s current price.

A number of other analysts have also recently weighed in on TERN. TD Cowen cut shares of Terns Pharmaceuticals from a “buy” rating to a “hold” rating and set a $53.00 target price on the stock. in a research note on Thursday. HC Wainwright reiterated a “neutral” rating and issued a $53.00 price target (down from $60.00) on shares of Terns Pharmaceuticals in a research note on Wednesday, March 25th. Jefferies Financial Group reissued a “buy” rating and set a $70.00 price objective on shares of Terns Pharmaceuticals in a report on Wednesday, December 10th. Mizuho lowered Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, Leerink Partners initiated coverage on Terns Pharmaceuticals in a report on Monday, February 9th. They issued an “outperform” rating and a $58.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $56.60.

Terns Pharmaceuticals Trading Down 0.1%

NASDAQ TERN traded down $0.05 during trading on Monday, hitting $52.88. 1,999,894 shares of the company’s stock were exchanged, compared to its average volume of 3,942,018. The company has a market cap of $5.49 billion, a PE ratio of -51.33 and a beta of -0.31. Terns Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $53.19. The stock’s 50 day moving average price is $41.28 and its two-hundred day moving average price is $29.36.

Insider Buying and Selling at Terns Pharmaceuticals

In other news, CEO Amy L. Burroughs sold 71,339 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the completion of the transaction, the chief executive officer owned 138,976 shares of the company’s stock, valued at approximately $5,294,985.60. This trade represents a 33.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the transaction, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 170,409 shares of company stock valued at $6,563,769 in the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Terns Pharmaceuticals in the fourth quarter worth approximately $25,000. GAMMA Investing LLC lifted its position in shares of Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after purchasing an additional 770 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Terns Pharmaceuticals by 61.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock valued at $89,000 after purchasing an additional 841 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Terns Pharmaceuticals by 5.1% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 18,555 shares of the company’s stock worth $750,000 after buying an additional 906 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Terns Pharmaceuticals by 29.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,377 shares of the company’s stock valued at $177,000 after buying an additional 994 shares during the period. Institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.